Treats pain associated with true trigeminal neuralgia. ANDA 207798, held by Umedica. Carbamazepine.
As of Nov 16, 2026, ANDA 207798 (Carbamazepine), held by Umedica, was first approved by FDA on Apr 15, 2020, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Epilepsy Carbamazepine is indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: 1. Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvement than those with other types. 2. Generalized tonic-clonic seizures (grand mal). 3. Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petit mal) do not appear to be controlled by carbamazepine (see PRECAUTIONS, General).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 15, 2020 | Original application | Approved | None posted |
| Carbamazepine100MG · tablet;oral | Carbamazepine | Rx |
| Carbamazepine200MG · tablet;oral | Carbamazepine | Rx |
| Jul 29, 2026 | Supplement 23Labeling · Standard review | Approved | None posted |
| Dec 22, 2023 | Supplement 11Labeling · Standard review | Approved | None posted |
| Apr 15, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters